Bristol Myers Squibb Reports First Quarter Financial Results for 2024
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Bristol-Myers Squibb Co. (BMY) PT Lowered to $53 at Deutsche Bank
April 29, 2024 5:27 AM EDTDeutsche Bank analyst James Shin lowered the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $53.00 (from $55.00) while maintaining a Hold rating.
The analyst comments "We get it - BMY's cost cut is poor optics given low visibility for late-decade revenues and... More
Bristol-Myers Squibb (BMY) stock slips despite earnings beat
April 25, 2024 7:09 AM EDT(Updated - April 25, 2024 7:26 AM EDT)
Bristol-Myers Squibb (NYSE: BMY) reported better-than-expected earnings and revenue for the first quarter of 2024.
Still, BMY stock fell by 1.7% in premarket trading.
The company reported a loss per share of $4.40, compared to the estimated loss per share of $4.47. Revenue for the quarter reached $11.9 billion, exceeding the consensus... More
Bristol-Myers Squibb (BMY) Tops Q1 EPS by 7c, Beats on Revenue
April 25, 2024 7:00 AM EDTBristol-Myers Squibb (NYSE: BMY) reported Q1 EPS of ($4.40), $0.07 better than the analyst estimate of ($4.47). Revenue for the quarter came in at $11.9 billion versus the consensus estimate of $11.46 billion.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
... More